Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
right timing I guess.. lol. I didn't play this one but if anyone did buy and hold for 9 months, they would be millionaires.. right before January of 2016, the PPS was $0.004... imagine putting a $1,000 gamble and holding. even after a couple months the price shot up to $0.40-0.50.
congrats to those who played this properly. for those who didn't, im sorry.. you're going to lose a little before you get it right.
it's a typical pump and dump.. be careful because the bottom will eventually fall out leaving inexperienced traders with shares of a useless company and big losses.
Correction
"otherwise I COULDN'T live with myself knowing I made money when these people are suffering."
Longtrailer - thanks for the info. I too saw that article as well. there's a lot of positives here and I hope they share information about a Phase 3 trial. after they released Phase 2 results, they said they'll be meeting with the Phase 2 participants to let them know who received treatment and who were the placebos. once that occurs, they were going to meet with FDA to go over results. after that happens, I assume we'll hear something about the meeting and plan moving into Phase 3.
Funding is always a concern at these stages for biotech companies but I personally feel with their treatment results, an investor or grants shouldn't be hard to find. I prefer they raise capital through grants or private investor and not get an loans or stock agreements with larger pharmaceutical company. where they stand right now, they have cash and no debt. the problem moving forward is how to fund the Phase 3.
Regardless, I really hope their product is good for the people who need it the most. Personally, I have mixed feelings about investing with this company. if I make money, I plan to donate all of it to ALS R&D. otherwise I could live with myself knowing I made money when these people are suffering.
wow great stuff, thanks for sharing.
anyone care to speculate as to what the stock price could be assuming the phase 3 trial is a multi dose trial?
just curious.
things have been pretty quiet with the company since the phase 2 results.
I was commenting on the reaction of traders to the news. Seems like most of them were in it to make a quick buck which I understand. As for the company, I'd have to disagree. They have done everything they said they would do. They up listed from the OTC to NASDAQ. Look at the situation, biotech small cap company still in their research and development stages. Results and news typically move these stocks which is why it was funny to me with stock trading down. Personally, in the short term I don't care. I'm here for the long term and think there's huge upside to this company especially for the patients. Good luck with your trading.
this is funny, the company releases great results to their phase 2 trial and the stock continues to go down... meanwhile, if apple released a new toy, their stock would go through the roof.
anyways, im buying up as much as I can. I know the money will help in some way to go towards the trials.
it's already "cheap" relative to the potential upside. everyone trades stocks for different reasons. 90% of my stock investing is for retirement but I do trade a few stocks for short term gains. this company could be in the category of making money from short and long term positions. for me, im looking long term. if there's great news, then this will be trading much higher. if all goes well, several years down the road we could be around $20-30/share. other biotech companies have succeeded and in my opinion, BCLI is in the position to do the same.
A company wouldn't announce a presentation days in advance to give bad news. if you're looking for cheap shares, you're not going to see $2 (unless something really bad happens).
lets not lose sight as who the real winners are here, it's not the investor....it's the ALS patient.
Dude go away with your stupid post. Brainstorm is trying to do good things and yes their stock will increase with anticipation of good news ahead of their phase 2 results call. This company is working hard to help others and your post is typical ignorance and sad tactics.
i saw one of those headlines on google finance that claimed this stock could go to $131/share?? lol. anyway, curious to see what everyone thought. seems like this company has potential which is why I bought a small position.
I can't find the link, it must of been removed which is more proof that the analysis wasn't real.
any idea of what price per share this will go?
just looking at the post.. looking to jump in for a quick ride!
yea, I find this rather strange because when Tony was hired, nothing was mentioned about him being an interim CEO. after reading the PR, it makes sense for the company to have someone who's been there for such a long time and has millions invested. in my opinion, companies that have CEO's invested run a tighter ship in terms of finances and direction, similarly with dividend paying stocks. dividend stock paying companies are more responsible with their finances.
regardless, I think it's a better fit for the company and this stock won't do much until we see the phase 2 results in Q2 2016.
im holding a long position so, im invested in the product and the company.. I think what they offer is great and rewarding to know their helping people.
jugs - go here.
mes·en·chy·mal
http://www.merriam-webster.com/dictionary/mesenchymal
it's been trading around $3.70-$3.90 and id say if you can enter around there, that would be good.. I haven't look at the technical data lately so my thoughts are speculative. just a few days ago, it was under $4/share and today it's up around $4.30 so we know it's volatile. maybe wait for it to go back down before re-entry (which I know you would do this but I like to reassure).
jugs - im reposting what I said in post 2141 which I think gives a good reason why this board isn't spammed like other boards. plus these companies rely on their clinical results to keep the company moving forward. without that, they can't get investors like us or larger ones. I think until we see more clinical results reported from the company, it'll be slow around here.
- i will give you my opinion from two perspectives.
1. emotional perspective - if my analysis of this company is based on what they're trying to accomplish and improve quality of life for debilitating neurodegenerative diseases and stock price with little research, then I think it's a "good buy." they are expanding into other markets/clinics like we've seen from their positive results with autism. my brother-in-law's wife has MS and i'd love to see this company be an option for her in the future (or anyone else for that matter). also, this form of treatment is an alternative for those who want to avoid pharmaceuticals.
2. investing perspective - low stock price, great clinical results, safe method of treatment, only 1 competitor in the market now, debt free, fully funded through their trails. as mentioned in the presentation, their burn rate is approx. 2M/quarter and they raised 16M from warrants. most of their funding is private or through grants in addition to warrants being exercised. if you look at how their warrants are being exercised, tony mentions the details in the presentation. I don't want to attempted the explanation because i'll probably not give the correct detail. it's at the end around minute 19 if you want to fast-forward.
of course the biotech sector has cons, risky, volatile stocks, and gaining FDA approval takes time. the good thing is this company was approved for fast-track so, this will speed things up and I think as long as they continue to have positive results, it's worth paying attention.
minding - I think your approach is good in that you're sitting back but you may want to keep this on the radar this year as we get closer to results in 2016. you might see an uptrend as investors prepare for good news. if you plan on jumping back in before any major announcements this year is probably this best time to buy (in my opinion).
Minding - i will give you my opinion from two perspectives.
1. emotional perspective - if my analysis of this company is based on what they're trying to accomplish and improve quality of life for debilitating neurodegenerative diseases and stock price with little research, then I think it's a "good buy." they are expanding into other markets/clinics like we've seen from their positive results with autism. my brother-in-law's wife has MS and i'd love to see this company be an option for her in the future (or anyone else for that matter). also, this form of treatment is an alternative for those who want to avoid pharmaceuticals.
2. investing perspective - low stock price, great clinical results, safe method of treatment, only 1 competitor in the market now, debt free, fully funded through their trails. as mentioned in the presentation, their burn rate is approx. 2M/quarter and they raised 16M from warrants. most of their funding is private or through grants in addition to warrants being exercised. if you look at how their warrants are being exercised, tony mentions the details in the presentation. I don't want to attempted the explanation because i'll probably not give the correct detail. it's at the end around minute 19 if you want to fast-forward.
of course the biotech sector has cons, risky, volatile stocks, and gaining FDA approval takes time. the good thing is this company was approved for fast-track so, this will speed things up and I think as long as they continue to have positive results, it's worth paying attention.
minding - I think your approach is good in that you're sitting back but you may want to keep this on the radar this year as we get closer to results in 2016. you might see an uptrend as investors prepare for good news. if you plan on jumping back in before any major announcements this year is probably this best time to buy (in my opinion).
my pleasure... as always everyone should do their own research and form opinion about the company. i'd like to see this one jump up 50% like it did back in December 2014 after positive results of their clinical trials. I didn't sell any shares which I probably should of took the gain, then bought again at these levels. unfortunately, I wasn't near my computer to do so but im not mad about the missed opportunity. I think the stock will be higher in the future and those who are holding will be rewarded.
this is all my opinion. aside from the speculation of the stock, the companies position right now is poised and ready to move forward. I think once more results are released this year and next year, the stock will catch up.
Minding - i'm listening to it now (Tuesday feb. 10). it's a good summary of the treatment and current status of how their trials are going. it's worth registering on the link you sent and listening to the presentation. it's about 24 minutes. Tony mentions there's only 1 form of treatment currently on the market called Riluzole (slide 6). you may know this already but it was news to me. you could research the drug and probably compare the differences to brainstorm's alternative.
personally - I think the stock is undervalued as tony mentions at the end of the presentation considering their clinical results. in my opinion, the US clinical results that will be available Q2 of 2016 will make this stock soar. of course, FDA approval would make this a real winner but we'll see where it goes. the fact that they raised 16M from warrants and burn approximately 2M/quarter will allow them to continue research. I think it's a great company, I like what they're doing and who they're providing their service for. im in this one for the long run and I like where it's going.
yea i don't see it as an issue.. i was responding another post on this website. im invested with BCLI and looking forward to the clinical trial results.
i wouldn't pay much attention to people who make comments without proof to support.. at the every least dannytrades should provide the directors name but if he did any research, he would know that all management has exclusive backgrounds in medical and biotechnoloy field. i think dannytrades is just another example of someone trying to bash the stock for their own agenda. i can make outrages claims too.....for instance, "i have webbed feet and i invented the question mark."
see, now it's dannytrades turn.... lol
i'm not sure why the great response either.. i thought we had better news when we uplisted to the NASDAQ but i'll take it either way. i think it's because of Fiorino's background playing into the stock peak.
in that same artical it states he didn't like bio tech stocks in his portfolio but he left that to become a CEO of one. that itself would attrack people to look over the company profile.
im down in my investment because i bought prior to the split but holding strong..
you're welcome.. hopefully the links i sent out are ligit and this time tomorrow, we'll be on the NASDAQ.. good stuff!
yes i agree to say the least.. i just saw this link on google finance under the ticker BCLID.
http://www.reuters.com/article/2014/09/29/brainstorm-cell-nasdaq-idUSL6N0RT0L420140929
hey everyone, sorry for the delay.. i saw someone else post the same thing on thursday i believe but i found the same info.. that's what my previous post meant to say. i haven't found official news from Brainstorm's website but it appears that after september 30th, it'll be trading on the NASDAQ...
i found the information below on google finance where if you type in BCLID, you'll see the link from the latest news feed on thursday (sept 25th).
Brainstorm Cell Therapeutics : Receives Approval for Uplisting to the NASDAQ Capital Market
09/24/2014 | 05:59pm US/EasternRecommend: 0 NEW YORK, NEW YORK AND PETACH TIKVAH, ISRAEL , United States, via ETELIGIS INC., 09/24/2014 - - BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI, BCLID ), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market, and hopes to commence trading on the NASDAQ Capital Market when trading begins on September 30, 2014.
http://www.4-traders.com/BRAINSTORM-CELL-THERAPEUT-18044793/news/Brainstorm-Cell-Therapeutics--Receives-Approval-for-Uplisting-to-the-NASDAQ-Capital-Market-19096523/
http://www.itbusinessnet.com/article/BrainStorm-Receives-Approval-for-Uplisting-to-the-NASDAQ-Capital-Market-3514536
good stuff, they been approved to uplist to the NASDAQ..
BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment Conference
NEW YORK, NY and PETACH TIKVAH, ISRAEL , United States, via ETELIGIS INC., 09/04/2014 - - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate overview of BrainStorm and NurOwn, its proprietary stem cell platform currently in a phase 2 trial in Amyotrophic Lateral Sclerosis. Details of the presentation are as follows:
Rodman and Renshaw 16th Annual Global Investment Conference
Date: Tuesday, September 9, 2014
Time: 1:40-2:05 PM EST
Location: New York Palace Hotel, New York, NY
Room: Kennedy II Salon (4th Floor)
The presentation will be webcast, which can be accessed at the following link (http://wsw.com/webcast/rrshq24/bcli) or through the Investor section of the BrainStorm website.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website atwww.brainstorm-cell.com.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as may, should, would, could, will, expect, likely, believe, plan, estimate, predict, potential, and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorms forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or managements beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Contact
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Tony Fiorino, MD, PhD
Chief Executive Officer
Phone: (646) 666-3188
info@brainstorm-cell.com
US Investor Contact
LifeSci Advisors, LLC
Michael Rice
Phone: (646) 597-6979
mrice@lifesciadvisors.com
SOURCE: BrainStorm Cell Therapeutics, Inc.
i saw BCLI issued shares? or they were buying?
this is an area im not familiar with when companies file multiple "Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)"
i believe the meeting is tomorrow.
thanks for the info, that is great news..
looks false to me too.. for starters it says BCLI is listed on the NASDAQ.
ah well, maybe this will bring positive attention and not someone trying to pump the stock.
i hope they don't vote for the RS in the upcoming meeting. im down 10% since buying, i should of held out until after the meeting but i jumped in. now i think it was too soon, stupid move on my part but there's some upside to it all.
very true and i agree.. im being hopeful but i do understand the reality of it all.
i like how you think.
can someone post an L2? im curious to see how the bids are stacking (if any).
hopefully no RS during this meeting.. i think with positive results through the clinical trials and more american awareness of this company, this will move up easily..
if BCLI is looking to uplist, they should let the stock breathe and give it time to go up because it will in the future.
yea me too. im sure they'll want to uplist asap to get more exposure however it would be nice to see company results drive the stock higher creating more shareholder confidence..
decisions decisions.. maybe i can make a few dollars on both plays but overall, i like how this company is progressing even though they're smallcap.
thanks...
any thoughts on the possible reverse split which the board will vote on come august 14th. i got the info from their recent 14a filing regarding the shareholder meeting.
2. To authorize the Board of Directors, in its discretion, should it deem it to be appropriate and in the best interests of the Company and its stockholders, to amend the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of Common Stock by a ratio of between 1-for-10 and 1-for-20, inclusive, without further approval or authorization of the Company’s stockholders;
anyone have an L2 they can post? i've been watching/researching this company for a couple weeks and really like what i see.. i dont like the lack of shareholder confidence however, i know there's a lot of private funding and other investors who have a lot of confidence in this company..
im definitely going to buy in for long term and hoping to jump in at a low point.
good to this company fighting back..
http://www.valuewalk.com/2014/04/organovo-sues-short-seller-simeon-research/
i haven't researched this company enough but it "appears" to have something going for them however we all should keep in mind it's trading in penny land... i will 99.9% never buy another penny stock because it's a waste of time, money, and effort. more importantly, MONEY.
i'll keep looking but to be honest, i wasn't impressed by OUYA.. i like the concept but the games are 8 bit, reminds me of nintendo when i was younger. the idead of technology is to improve things and i don't see much value when you have Xbox, playstation, and Nvidia Shield.
this where the company has to prove me wrong and show more than "book value." i want to see sales, revs, etc.